AZN.L - AstraZeneca PLC

LSE - LSE Delayed price. Currency in GBp
5,478.00
+50.00 (+0.92%)
At close: 4:51PM BST
Stock chart is not supported by your current browser
Previous close5,428.00
Open5,469.00
Bid5,400.00 x 6100
Ask5,500.00 x 13000
Day's range5,435.00 - 5,490.00
52-week range4,260.00 - 5,520.00
Volume1,901,729
Avg. volume2,326,843
Market cap69.387B
Beta0.98
PE ratio (TTM)23.11
EPS (TTM)237.00
Earnings date26 Jul 2018
Forward dividend & yield2.02 (4.06%)
Ex-dividend date2018-02-15
1y target est72.97
  • Reuters6 hours ago

    Oil weighs on FTSE, Kingfisher shines

    By Julien Ponthus LONDON (Reuters) - A slump in oil prices hit British majors on Friday, limiting the gains of the FTSE 100 benchmark index while Kingfisher shone after Australia's Wesfarmers (WES.AX) ...

  • Reuters - UK Focus6 hours ago

    Oil weighs on Britain's FTSE, Kingfisher shines

    A slump in oil prices hit British majors on Friday, limiting the gains of the FTSE 100 benchmark index while Kingfisher shone after Australia's Wesfarmers said it would sell rival UK home improvement chain ...

  • Reuters - UK Focus13 hours ago

    Britain's FTSE rebounds, Kingfisher jumps as Homebase changes hands

    Kingfisher led a rebound in UK shares on Friday amid relief on global markets about Pyongyang's measured response to the canceling of the summit between the United States and North Korea. At 0900 GMT, ...

  • Reuters15 hours ago

    AstraZeneca cancer drug hits second goal by extending survival

    AstraZeneca's (AZN.L) immunotherapy drug Imfinzi has hit a second important goal by improving overall survival in lung cancer patients, boosting prospects for a medicine that has already got off to a promising commercial launch. Imfinzi is the first immunotherapy to be approved in this setting, giving AstraZeneca a chance to intervene relatively early in lung cancer.

  • Reuters - UK Focus15 hours ago

    AstraZeneca cancer drug hits second goal by extending survival

    AstraZeneca (NYSE: AZN - news) 's immunotherapy drug Imfinzi has hit a second important goal by improving overall survival in lung cancer patients, boosting prospects for a medicine that has already got off to a promising commercial launch. Imfinzi is the first immunotherapy to be approved in this setting, giving AstraZeneca a chance to intervene relatively early in lung cancer. Analysts believe using Imfinzi in stage III lung cancer, where cancer has only spread locally, opens up a multibillion-dollar sales opportunity and the latest overall survival (OS) data should underline the drug's potential.

  • MarketWatch4 days ago

    U.K. stocks log record close as U.S.-China ease trade-war tensions

    U.K. stocks rose sharply on Monday, scoring a record close, as traders welcomed news over the weekend that China and the U.S. reached an agreement that eases trade tensions between the world’s two largest economies. The FTSE 100 index (^FTSE) rose 1% to end at 7,859.17, taking out its previous closing high of 7,787.97, hit last Thursday. A weaker pound tends to boost the FTSE 100, as the index’s components conduct the bulk of their business overseas and a softening in sterling lifts revenue when converted back into the U.K. currency.

  • AstraZeneca's Lokelma Gains FDA Nod to Treat Hyperkalemia
    Zacks4 days ago

    AstraZeneca's Lokelma Gains FDA Nod to Treat Hyperkalemia

    AstraZeneca's (AZN) Lokelma secures an FDA approval for the treatment of hyperkalemia in adults.

  • AstraZeneca potassium drug finally approved, threatening Vifor
    Reuters4 days ago

    AstraZeneca potassium drug finally approved, threatening Vifor

    The decision by U.S. regulators to finally approve AstraZeneca's (AZN.L) much-delayed excess potassium drug Lokelma gives the group another new medicine launch, boosting its portfolio as it strives to offset declining sales of older products. The U.S. Food and Drug Administration (FDA) had turned down the drug, formerly known as ZS-9, two times previously, casting doubt over AstraZeneca's decision to buy its original developer ZS Pharma for $2.7 billion (2 billion pounds) in 2015. Analysts, reacting to the approval announced late on Friday, said on Monday that the label for Lokelma was modestly better than for Vifor Pharma's (VIFN.S) rival therapy Veltassa, which also treats excess potassium levels or hyperkalemia.

  • Reuters - UK Focus4 days ago

    AstraZeneca potassium drug finally approved, threatening Vifor

    The decision by U.S. regulators to finally approve AstraZeneca (NYSE: AZN - news) 's much-delayed excess potassium drug Lokelma gives the group another new medicine launch, boosting its portfolio as it strives to offset declining sales of older products. The U.S. Food and Drug Administration (FDA) had turned down the drug, formerly known as ZS-9, two times previously, casting doubt over AstraZeneca's decision to buy its original developer ZS Pharma (NasdaqGM: ZSPH - news) for $2.7 billion in 2015. Analysts, reacting to the approval announced late on Friday, said on Monday that the label for Lokelma was modestly better than for Vifor Pharma's rival therapy Veltassa, which also treats excess potassium levels or hyperkalemia.

  • Reuters - UK Focus5 days ago

    BUZZ-AstraZeneca: FDA approves co's potassium control drug

    ** Shares of AstraZeneca up 2 pct after co's potassium control drug approved in the US ** Stock top pct gainer on the FTSE 100 ** Co's Lokelma approved in the US for the treatment of adults with hyperkalaemia, ...

  • AstraZeneca Blockbuster Is Flailing — Will Cancer Drugs Fill The Hole?
    Investor's Business Daily7 days ago

    AstraZeneca Blockbuster Is Flailing — Will Cancer Drugs Fill The Hole?

    AstraZeneca dipped early Friday after the U.K.-based pharmaceutical company lagged first-quarter expectations for sales and core earnings.

  • Pharma Stock Roundup: Zoetis to Buy Abaxis, NVS Gets FDA Nod for Migraine Drug
    Zacks7 days ago

    Pharma Stock Roundup: Zoetis to Buy Abaxis, NVS Gets FDA Nod for Migraine Drug

    Novartis' (NVS) CGRP antibody, Aimovig gains FDA approval for prevention of migraine. Zoetis (ZTS) and Lilly (LLY) announce deals to buy smaller companies.

  • Astrazeneca PLC (AZN) Q1 2018 Earnings Conference Call Transcript
    Motley Fool7 days ago

    Astrazeneca PLC (AZN) Q1 2018 Earnings Conference Call Transcript

    AZN earnings call for the period ending March 31, 2018.

  • AstraZeneca pay report rejected by 35 percent of shareholders
    Reuters7 days ago

    AstraZeneca pay report rejected by 35 percent of shareholders

    More than a third of AstraZeneca shareholders staged a revolt over bonuses at the pharmaceutical company on Friday, following concerns about levels of disclosures and outcomes under the company's incentive scheme. The rebellion is a blow for Chief Executive Pascal Soriot, who earlier reported first-quarter financial results that missed analysts' forecasts, but did provide evidence that the company's new drugs were growing strongly. "AstraZeneca engaged with its major shareholders during 2017 and is disappointed that enhancements made to remuneration report disclosures and changes to the operation of the annual bonus scheme in response to shareholder feedback have not significantly improved the voting result," the company said.

  • AstraZeneca pay report rejected by 35 percent of shareholders
    Reuters7 days ago

    AstraZeneca pay report rejected by 35 percent of shareholders

    More than a third of AstraZeneca shareholders staged a revolt over bonuses at the pharmaceutical company on Friday, following concerns about levels of disclosures and outcomes under the company's incentive scheme. The rebellion is a blow for Chief Executive Pascal Soriot, who earlier reported first-quarter financial results that missed analysts' forecasts, but did provide evidence that the company's new drugs were growing strongly. "AstraZeneca engaged with its major shareholders during 2017 and is disappointed that enhancements made to remuneration report disclosures and changes to the operation of the annual bonus scheme in response to shareholder feedback have not significantly improved the voting result," the company said.

  • Reuters - UK Focus7 days ago

    AstraZeneca pay report rejected by 35 pct of shareholders

    More than a third of AstraZeneca (Swiss: AZN.SW - news) shareholders staged a revolt over bonuses at the pharmaceutical company on Friday, following concerns about levels of disclosures and outcomes under the company's incentive scheme. The rebellion is a blow for Chief Executive Pascal Soriot, who earlier reported first-quarter financial results that missed analysts' forecasts, but did provide evidence that the company's new drugs were growing strongly. "AstraZeneca (NYSE: AZN - news) engaged with its major shareholders during 2017 and is disappointed that enhancements made to remuneration report disclosures and changes to the operation of the annual bonus scheme in response to shareholder feedback have not significantly improved the voting result," the company said.

  • MarketWatch7 days ago

    U.K. stocks fall from record as AstraZeneca, mining stocks decline

    FTSE 100 on track for longest weekly win run since 2005ReutersAstraZeneca shares are losing ground Friday. U.K. stocks ended lower on Friday, pulling back from the previous session’s record close, as shares of AstraZeneca declined following the heavyweight drugmaker’s earnings report, and as shares in mining companies skidded in the wake of a selloff in metals prices. The FTSE 100 index (^FTSE) dropped 0.1% to close at 7,778.79, breaking a three-day winning streak.

  • Commodities help FTSE seal eight-week winning streak
    Reuters7 days ago

    Commodities help FTSE seal eight-week winning streak

    Britain's leading stock index posted its eighth straight week of gains despite dipping slightly on Friday as investor enthusiasm waned following the previous day's record close. The FTSE 100 ended the session down 0.1 percent at 7,778.79 points, in line with the FTSE 250 which hit a fresh record earlier in the session before turning lower. The FTSE sealed its longest winning streak in 13 years, marking a strong comeback for British stocks.

  • Reuters - UK Focus7 days ago

    Commodities help FTSE seal eight-week winning streak

    Britain's leading stock index posted its eighth straight week of gains despite dipping slightly on Friday as investor enthusiasm waned following the previous day's record close. The FTSE 100 ended the ...

  • Reuters - UK Focus7 days ago

    LIVE MARKETS-Closing snapshot: STOXX posts best weekly streak since 2014

    Welcome to the home for real-time coverage of European equity markets brought to you by Reuters stocks reporters and anchored today by Danilo Masoni. Reach him on Messenger to share your thoughts on market ...

  • Reuters - UK Focus7 days ago

    LIVE MARKETS-France vs Germany: here's a reality-check for Macron believers

    Welcome to the home for real-time coverage of European equity markets brought to you by Reuters stocks reporters and anchored today by Danilo Masoni. Reach him on Messenger to share your thoughts on market ...

  • Reuters - UK Focus7 days ago

    LIVE MARKETS-Italy: no surprises there

    Welcome to the home for real-time coverage of European equity markets brought to you by Reuters stocks reporters and anchored today by Danilo Masoni. Reach him on Messenger to share your thoughts on market ...

  • Reuters - UK Focus7 days ago

    LIVE MARKETS-Strong dollar a boost for European equities

    Welcome to the home for real-time coverage of European equity markets brought to you by Reuters stocks reporters and anchored today by Danilo Masoni. Reach him on Messenger to share your thoughts on market ...

  • AstraZeneca's (AZN) Q1 Earnings & Sales Miss, Stock Down
    Zacks7 days ago

    AstraZeneca's (AZN) Q1 Earnings & Sales Miss, Stock Down

    AstraZeneca (AZN) misses earnings and sales estimates in the first quarter. It maintains its previously issued outlook for 2018.

  • Reuters - UK Focus7 days ago

    LIVE MARKETS-Why European shares can relax about bond yields (and the U.S. can't)

    Welcome to the home for real-time coverage of European equity markets brought to you by Reuters stocks reporters and anchored today by Danilo Masoni. Reach him on Messenger to share your thoughts on market ...

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes